MARKET

GPCR

GPCR

Structure Therapeutics Inc ADR
NASDAQ
25.57
-1.25
-4.66%
After Hours: 26.49 +0.92 +3.60% 17:01 05/09 EDT
OPEN
26.65
PREV CLOSE
26.82
HIGH
27.12
LOW
25.51
VOLUME
599.27K
TURNOVER
--
52 WEEK HIGH
62.74
52 WEEK LOW
13.22
MARKET CAP
1.47B
P/E (TTM)
-10.9856
1D
5D
1M
3M
1Y
5Y
1D
Piper Sandler Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 14h ago
Stifel Nicolaus Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 16h ago
Buy Rating for Structure Therapeutics: Promising Phase 2b Results and Strategic Market Positioning
TipRanks · 17h ago
Promising Developments in Weight Management Propel Buy Rating for Structure Therapeutics
TipRanks · 19h ago
Structure Therapeutics Reports Increased Losses Amid Rising R&D Costs
TipRanks · 1d ago
Structure Therapeutics reports Q1 results
Seeking Alpha · 1d ago
Press Release: Structure Therapeutics Reports -2-
Dow Jones · 1d ago
Press Release: Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights
Dow Jones · 1d ago
More
About GPCR
More
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Recently
Symbol
Price
%Change

Webull offers Structure Therapeutics Inc (ADR) stock information, including NASDAQ: GPCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GPCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GPCR stock methods without spending real money on the virtual paper trading platform.